Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 5
1985 11
1986 24
1987 41
1988 61
1989 69
1990 60
1991 81
1992 83
1993 103
1994 94
1995 108
1996 80
1997 93
1998 113
1999 154
2000 154
2001 271
2002 353
2003 384
2004 476
2005 575
2006 833
2007 1017
2008 1149
2009 1336
2010 1457
2011 1718
2012 1677
2013 1758
2014 1793
2015 1661
2016 1918
2017 2310
2018 2396
2019 2619
2020 2950
2021 2829
2022 2303
2023 1932
2024 826

Text availability

Article attribute

Article type

Publication date

Search Results

32,594 results

Results by year

Filters applied: . Clear all
Page 1
Tezepelumab: First Approval.
Hoy SM. Hoy SM. Drugs. 2022 Mar;82(4):461-468. doi: 10.1007/s40265-022-01679-2. Drugs. 2022. PMID: 35184265 Review.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
Teplizumab.
Beninger P. Beninger P. Clin Ther. 2023 Jul;45(7):684. doi: 10.1016/j.clinthera.2023.05.003. Epub 2023 May 29. Clin Ther. 2023. PMID: 37258327 No abstract available.
Bimekizumab-bkzx.
Mitrić MM. Mitrić MM. Clin Ther. 2024 Apr;46(4):379-380. doi: 10.1016/j.clinthera.2024.03.009. Epub 2024 May 4. Clin Ther. 2024. PMID: 38705824 No abstract available.
Tralokinumab-ldrm.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2022 Apr 1;79(8):616-617. doi: 10.1093/ajhp/zxac020. Am J Health Syst Pharm. 2022. PMID: 35267017 No abstract available.
Nemolizumab for atopic dermatitis.
Labib A, Vander Does A, Yosipovitch G. Labib A, et al. Drugs Today (Barc). 2022 Apr;58(4):159-173. doi: 10.1358/dot.2022.58.4.3378056. Drugs Today (Barc). 2022. PMID: 35412530 Review.
Anifrolumab-fnia.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2021 Nov 9;78(22):1999-2001. doi: 10.1093/ajhp/zxab334. Am J Health Syst Pharm. 2021. PMID: 34492094 No abstract available.
Tremelimumab-actl.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2023 Mar 7;80(6):324-328. doi: 10.1093/ajhp/zxac365. Am J Health Syst Pharm. 2023. PMID: 36645069 No abstract available.
32,594 results
You have reached the last available page of results. Please see the User Guide for more information.